Helicobacter pylori Eradication Therapy Ameliorates Latent Digestive Symptoms in Chronic Atrophic Gastritis

Yamada, Shinya; Tomatsuri, Naoya; Kawakami, Takumi; Nakatsugawa, Yoshikazu; Nishimura, Takeshi; Fujii, Hideki; Sato, Hideki; Okuyama, Yûsuke; Kimura, Hiroyuki; Yoshida, Naohisa

doi:10.1159/000486618

Cited by 13 publications

(4 citation statements)

References 34 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors concluded that H. pylori eradication improved the QOL, especially in patients who had an impaired QOL before eradication . Similar results were reported by Yamada et al , who studied 650 patients with chronic atrophic gastritis and latent digestive symptoms including dyspepsia, and found a significant and persistent (up to 1 year) improvement after H. pylori eradication …”

Section: Helicobacter Pylori Infection and Dyspepsiasupporting

confidence: 79%

“…The authors concluded that H. pylori eradication improved the QOL, especially in patients who had an impaired QOL before eradication. 25 Similar results were reported by Yamada et al, who studied 650 patients with chronic atrophic gastritis and latent digestive symptoms including dyspepsia, and found a significant and persistent (up to 1 year) improvement after H. pylori eradication 26. In an Indian study, 120 patients with dyspepsia were recruited.Fifty-five percent of them were H. pylori positive, 56.7% were positive for stress/anxiety/depression (SAD), and 29.2% for both.…”

supporting

confidence: 60%

See 1 more Smart Citation

Helicobacter pylori and nonmalignant upper gastrointestinal diseases

2018

View full text Add to dashboard Cite

The review of the most important recent publications concerning the relation of Helicobacter pylori with peptic ulcer disease (PUD), noninvestigated and functional dyspepsia, and gastroesophageal reflux disease (GERD) is presented. H. pylori remains the main etiopathogenetic factor in complicated and uncomplicated PUD. Nevertheless, the role of nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin is increasing. The novel data did not confirm that PUD caused by NSAIDs and aspirin is less symptomatic. The role of glucocorticoids, immunosuppressants, and antidepressants seems to be of some importance. Although the involvement of H. pylori in functional dyspepsia is controversial, several data support the importance of H. pylori-induced gastritis in the pathogenesis of dyspeptic symptoms. Recent interventional studies have reported that H. pylori eradication improves dyspepsia mainly in areas with a high prevalence of this bacterium. Novel data regarding the relation of gastrointestinal peptides, ghrelin and obestatin, with H. pylori infection are also presented. Intriguing findings support the involvement of the gastric microbiota in the causation of chronic functional dyspepsia. Finally, some data concerning negative, positive, or neutral associations of H. pylori with gastroesophageal reflux disease (GERD) were published. In this context, today there is no evidence indicating that H. pylori eradication could worsen the symptoms or the course of GERD.

show abstract

Section: Helicobacter Pylori Infection and Dyspepsiasupporting

confidence: 79%

supporting

confidence: 60%

Helicobacter pylori and nonmalignant upper gastrointestinal diseases

2018

View full text Add to dashboard Cite

show abstract

“…Both concomitant and hybrid eradication therapies had beneficial impacts on gastrointestinal symptoms in their total GSRS scores. A similar positive effect of eradication therapy has also been observed in earlier studies [ 18 , 19 ]. Additionally, a multicenter prospective study performed in 15 referral institutions on 165 H. pylori infected patients demonstrated that quality of life could be improved regardless of eradication outcome [ 18 ].…”

Section: Discussionsupporting

confidence: 88%

“…Reflux symptoms, maldigestion and abdominal pain are frequently associated with symptomatic H. pylori infection. Yet, the only beneficial role of successful eradication therapy, in the case of dyspeptic symptoms, is well-known, as previous studies have shown [ 8 , 19 ]. H. pylori gastritis can be the cause of dyspepsia in a subset of patients [ 20 , 21 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of Different Helicobacter pylori Eradication Therapies on Gastrointestinal Symptoms

et al. 2021

View full text Add to dashboard Cite

Background and Objectives: Helicobacter pylori (H. pylori) infection impairs quality of life. However, whether eradication therapy ameliorates gastrointestinal symptoms remains questionable. The main objective of this study was to evaluate the influence of H. pylori eradication therapy on gastrointestinal symptoms. Materials and Methods: A total of 140 patients, 59 women and 81 men, with a mean age of 61 and suffering from H. pylori infection in the University Hospital of Split, Croatia, were enrolled in the study. Patients were randomly assigned to either concomitant or hybrid therapies. The Gastrointestinal Symptom Rating Scale (GSRS) questionnaire was completed by patients prior to and after the eradication therapy. Results: In both groups, the total GSRS score improved significantly after therapy. In the concomitant group, the abdominal pain score, reflux symptoms score and indigestion score decreased significantly after therapy. In the group with hybrid therapy, all five groups of symptoms (abdominal pain, reflux symptoms, indigestion, diarrhea and constipation) significantly decreased after therapy. Patients with adverse events had significantly higher total GSRS scores after eradication therapy. Conclusions: H. pylori eradication therapy could alleviate gastrointestinal symptoms regardless of the treatment used, but the favorable effect seemed to be more pronounced after hybrid therapy.

show abstract